awmsg logo



valganciclovir (Valcyte®)


Reference No. 824

Publication date:
07/09/2011


Appraisal information

valganciclovir (Valcyte®) 50 mg/ml powder for oral solution


Company: Roche Products Ltd
BNF category: Infections
NMG meeting date: 11/05/2011
AWMSG meeting date: 15/06/2011
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 0711
Ministerial ratification: 01/09/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Valganciclovir (Valcyte®) powder for oral solution is recommended as an option for restricted use within NHS Wales for 200 days prophylaxis of cytomegalovirus (CMV) disease in CMV-negative kidney transplant patients who have received a transplant from a CMV-positive donor. Valganciclovir (Valcyte®) powder for oral solution is restricted for use in patients who cannot take tablets or with a CrCl<10 (ml/min). AWMSG is of the opinion that valganciclovir (Valcyte®) powder for oral solution is not suitable for shared care within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download